新型WRN酶抑制剂选择性地向微卫星-不稳定的癌细胞
Gabriele Picco1, Yanhua Rao2, Angham Al Saedi1
1Wellcome Sanger Institute, Cambridge, UK.
Cancer discovery
|April 8, 2024
概括
新的WRN螺旋酶抑制剂在治疗微卫星不稳定 (MSI) 癌症方面表现有前途. 这些向药物利用MSI瘤的漏洞,导致DNA损伤,并在临床前模型中抑制癌症生长.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 微卫星不稳定 (MSI) 癌症由于扩大的DNA (TA) n重复而表现出复制应激,从而产生对WRN酶的依赖.
- WRN螺旋酶是MSI瘤的验证合成致命标,目前正在开发的抑制剂.
研究的目的:
- 使用CRISPR-Cas9基编辑绘制MSI细胞中的关键WRN残留物.
- 为MSI癌症治疗开发强效和选择性的WRN化酶共价抑制剂.
- 在临床前模型中评估这些抑制剂的疗效和生物标志物相关性.
主要方法:
- 使用CRISPR-Cas9基编辑来识别关键的WRN残留物.
- 基于碎片的查,以发现抑制剂的发展.
- 在体外和体内研究使用MSI癌症模型,器官和患者衍生的异种移植.
- 生物标记分析包括TA重复扩张和不匹配修复改变.
主要成果:
- 验证了WRN基酶域作为主要药物标.
- 开发出强效和选择性的共价 WRN 酶抑制剂.
- 已证明选择性抑制MSI模型生长,诱导扩大TA重复时的DNA双链断裂,以及DNA损伤.
- 在免疫疗法耐药模型中证实有效性,并确定了预测生物标志物.
结论:
- 发现强效,选择性共价性WRN抑制剂为MSI癌症中合成致命向WRN提供了概念证明.
- 这些抑制剂为MSI癌症提供了潜在的新疗法策略,包括对免疫疗法耐药的癌症.
- 开发的化合物是进一步研究WRN生物学和癌症治疗的宝贵工具.
更多相关视频
06:10A Fluorescence-based Exonuclease Assay to Characterize DmWRNexo, Orthologue of Human Progeroid WRN Exonuclease, and Its Application to Other Nucleases
Published on: December 23, 2013
5.4K
07:23Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
Published on: May 30, 2025
288
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
DNA Helicases
21.3K
DNA unwinding helicase enzymes are a type of motor protein. Motor proteins can translocate along filaments or polymers using energy generated from ATP hydrolysis. Helicases are involved in all the important cellular processes where DNA unwinding is required, such as DNA replication, repair, recombination, and transcription. They are present in all living organisms, but vary in their structure, function, and mechanism of action. For example, in prokaryotes, DnaB helicase binds and translocates...
21.3K
lncRNA - Long Non-coding RNAs
8.6K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K
Drugs that Destabilize Microtubules
2.0K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K
siRNA - Small Interfering RNAs
16.7K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.7K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
